Last reviewed · How we verify
NCT06780007
Weight Loss Effect of Akkermansia Muciniphila in Obese Patients
NA trial testing Probiotic in 28≤BMI≤35Kg/m2 in 106 participants. Completed in 16 June 2025.
28 February 2025
Quick facts
| Lead sponsor | Wecare Probiotics Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 106 |
| Start date | 21 January 2025 |
| Primary completion | 28 February 2025 |
| Estimated completion | 16 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Probiotic
- Placebo
Conditions studied
- 28≤BMI≤35Kg/m2 — all drugs for 28≤BMI≤35Kg/m2 →
Sponsor
Wecare Probiotics Co., Ltd. — full company profile →
Who can join
Adults 18 to 65, any sex, with 28≤BMI≤35Kg/m2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study intends to study the effect of Akkermansia muciniphila on weight loss and the improvement of blood inflammation and metabolic indexes in obese patients with low Body Mass Index (BMI) through multi-center clinical studies, and for the first time to innovatively explore the weight loss mechanism of Akkermansia muciniphila by comparing the changes in brain function and fecal microbiota before and after intervention.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Combination of GLP-1 receptor agonist and Akkermansia muciniphila Akk11 reduces adiposity and ameliorates MASLD in T2D mice.
Gao K, Yin Z, Zhang C, Dong Z, et al · · 2026 · PMID 41526984 · DOI 10.1186/s13578-025-01525-4
Verify or expand the search:
- PubMed search for NCT06780007
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Probiotic
Trials testing the same drug.
- NCT07529457 — Akk09 in Adults With Constipation · NA · not yet recruiting
- NCT07507955 — Probiotics for Constipation Relief in Adults · NA · not yet recruiting
- NCT07462481 — Probiotic Improve Constipation · NA · recruiting
- NCT07511855 — Stress-buffering and Sleep Disturbance-resilient Effects of a Dual Bifidobacterium Longum Combination Under Short-term T · Phase 2 · not yet recruiting
- NCT07474064 — Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC · Phase 2 · not yet recruiting
Other Wecare Probiotics Co., Ltd. trials
Trials by the same sponsor.
- NCT07529457 — Akk09 in Adults With Constipation · NA · not yet recruiting
- NCT07507955 — Probiotics for Constipation Relief in Adults · NA · not yet recruiting
- NCT07462494 — Probiotic Intervention in Constipation · NA · not yet recruiting
- NCT07462481 — Probiotic Improve Constipation · NA · recruiting
- NCT07507929 — Probiotic for Weight Management in Overweight and Obese Adults · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06780007 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wecare Probiotics Co., Ltd.
- Last refreshed: 3 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06780007.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing